Analysis of efficacy of the SGLT2 inhibitor alone or in combination with the DPP-4 inhibitor on urinary and plasma DPP-4 activities in obese patients with type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Canagliflozin (Primary) ; Teneligliptin
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Apr 2017 Status changed from not yet recruiting to recruiting.
- 08 Oct 2015 New trial record